Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David R Staskin

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
The Journal of Urology|May 20, 2008
Urinary retention and post-void residual urine in men: separating truth from traditionSteven A Kaplan, Alan J Wein, David R Staskin, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 13, 2009
Extended-release trospium chloride improves quality of life in overactive bladderRoger R Dmochowski, Matt T Rosenberg, Norm R Zinner, et al.
International Urogynecology Journal and Pelvic Floor Dysfunction|September 4, 2009
Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndromePeter K Sand, Roger R Dmochowski, Norman R Zinner, et al.
The Journal of Urology|July 12, 2005
A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trialsAnnabel Nixon, Shoshana Colman, Luann Sabounjian, et al.
Neurourology and Urodynamics|April 5, 2011
Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptomsNorman R Zinner, Roger R Dmochowski, David R Staskin, et al.
Drugs & Aging|March 7, 2012
Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladderMichael B Chancellor, David R Staskin, Gary G Kay, et al.
The Journal of Urology|February 24, 2009
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter studyDavid R Staskin, Roger R Dmochowski, Peter K Sand, et al.
BJU International|August 17, 2010
Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndromePeter K Sand, Theodore M Johnson Ii, Eric S Rovner, et al.
Urology|April 19, 2006
Transdermal delivery of drugs for urologic applications: basic principles and applicationsVictor W Nitti, Steven Sanders, David R Staskin, et al.
Urology|November 26, 2009
Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladderRoger R Dmochowski, Kenneth M Peters, Jon D Morrow, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
The Journal of Urology|May 20, 2008
Urinary retention and post-void residual urine in men: separating truth from traditionSteven A Kaplan, Alan J Wein, David R Staskin, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 13, 2009
Extended-release trospium chloride improves quality of life in overactive bladderRoger R Dmochowski, Matt T Rosenberg, Norm R Zinner, et al.
International Urogynecology Journal and Pelvic Floor Dysfunction|September 4, 2009
Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndromePeter K Sand, Roger R Dmochowski, Norman R Zinner, et al.
The Journal of Urology|July 12, 2005
A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trialsAnnabel Nixon, Shoshana Colman, Luann Sabounjian, et al.
Neurourology and Urodynamics|April 5, 2011
Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptomsNorman R Zinner, Roger R Dmochowski, David R Staskin, et al.
Drugs & Aging|March 7, 2012
Blood-brain barrier permeation and efflux exclusion of anticholinergics used in the treatment of overactive bladderMichael B Chancellor, David R Staskin, Gary G Kay, et al.
The Journal of Urology|February 24, 2009
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter studyDavid R Staskin, Roger R Dmochowski, Peter K Sand, et al.
BJU International|August 17, 2010
Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndromePeter K Sand, Theodore M Johnson Ii, Eric S Rovner, et al.
Urology|April 19, 2006
Transdermal delivery of drugs for urologic applications: basic principles and applicationsVictor W Nitti, Steven Sanders, David R Staskin, et al.
Urology|November 26, 2009
Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladderRoger R Dmochowski, Kenneth M Peters, Jon D Morrow, et al.
Pageof 6